{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Fhsbiosimilars2-TuX0ksyX","width":444,"version":"1.0","type":"rich","title":"The Switch Pitch: Biosimilars In Real World HS Care PART 2","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/79ea1920-70b4-42ef-a520-d52b80fb3215/part2hsnew.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"🎙️ PART 2: HS & Biosimilars: The Switch Pitch — Real-World Pearls from the Clinic 💉🔥🧴\n\nIn Part 2 of our HS and biosimilars conversation, we’re getting practical — very practical. 🎧🩺\n\nFaculty Dr. Lauren Lam and Dr. Marni Wiseman join the Skin and Joints Podcast to unpack what really matters when biosimilars move from policy, paperwork, and prescribing forms… into the real lives of patients with hidradenitis suppurativa. 📋➡️💪\n\nFrom the science of biosimilarity and extrapolating evidence across inflammatory diseases, to the clinic-level details dermatologists cannot afford to overlook — injection pain, citrate-free formulations, device ergonomics, dosing convenience, patient support programs, rural drug delivery, reload strategies, and yes… whether the PSP actually calls the patient back. ☎️🚚💉\n\nBecause in HS, the best biologic or biosimilar is not just about the molecule. It is about momentum, access, trust, support, and getting treatment into the patient’s hands before they disappear from the care journey. 🧭🤝\n\nThe conversation also takes a timely turn into obesity, systemic inflammation, GLP-1/GIP therapies, and whether metabolic care may become part of the next frontier in HS management. ⚖️🔥🔬\n\nConsider this your field guide to biosimilar switching in HS — with clinic hot tips, PSP reality checks, and a reminder that sometimes the smallest formulation detail can make the biggest difference to the person injecting every week. 💡💉🙌\n\n\n\nLearning Objectives:By the end of this episode, listeners will be able to:\n\nExplain how biosimilar evidence may be extrapolated across inflammatory diseases and how this applies to real-world HS care. 🔬\nIdentify key formulation and device factors that may influence patient comfort, adherence, and treatment experience with adalimumab biosimilars. 💉\nDescribe the role of patient support programs (PSPs) in treatment initiation, onboarding, access, monitoring, and long-term engagement for patients with HS. 🤝\nRecognize practical barriers to biosimilar use in HS, including injection training, treatment delays, rural/remote medication delivery, and patient disillusionment. 🚚\nDiscuss emerging considerations around obesity, systemic inflammation, and GLP-1/GIP therapies as part of the evolving HS care conversation. ⚖️🔥=\n\n#SkinAndJointsPodcast #HidradenitisSuppurativa #HSawareness #Dermatology #MedicalDermatology #Biosimilars #Adalimumab #InflammatorySkinDisease #DermatologistEducation #RealWorldDermatology #PatientSupportPrograms #Biologics #ClinicalPearls #DermatologyPodcast #HSManagement 🧴💉🔥🎧🩺\n\n\n\nABOUT Dr. Lauren Lam BScH, MD, FRCPC\n\n​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB\n\nDr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures. She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date. \n\nBesides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.\n\n\n\nABOUT Dr. Marni C. Wiseman MD FRCPC DABD\n\nAssociate Professor, Section Head Dermatology University of Manitoba\n\nDirector, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research\n\nDr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice. \n\nDr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris.\n\nDr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.\n\n\n\nEPISODE SUPPORTED BY CELLTRION CANADA\n\n\n\n\n📻www.skinandjoints.ca\n\n✉️info@skinandjoints.ca\n\n\n\n"}